Clinical trials: Hepatitis A Virus
Hepatitis C
Can Vitamin D Supplementation Improve Hepatitis C Cure Rates
Evidence suggests that vitamin D may be directly or indirectly a co-factor for the efficacy of Hepatitis C virus, (HCV), antiviral therapies.
- Trial name
- ViaDUCT (NCT02053519)
- Testing
- Active Comparator: Vigantol Oil (Vitamin D3), Mygliol Oil
- Where
- 8 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Dundee
Chronic Hepatitis C
The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)
This is a randomized, double blind, multi-center, placebo controlled, three parallel arms, Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high dose onto the combination treatment (PegIFN…
- Trial name
- NCT01890200
- Testing
- Peginterferon alfa-2a, Ribavirin, TCM-700C
- Where
- 2 sites in China, Taiwan
- Sponsor
- TCM Biotech International Corp.
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Factors Associated to Success of Hepatitis C Therapy
The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means…
- Trial name
- NCT00514111
- Testing
- pegylated-interferon, conventional-interferon, ribavirin
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Hepatitis C
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
The purpose of this study is to evaluate the effect of cyclosporine, an anti-rejection drug, on the clearance of the hepatitis C virus in liver transplant subjects being treated with peg-interferon and ribavirin.
- Trial name
- NCT00821587
- Testing
- Cyclosporine, Tacrolimus
- Volunteers
- 39 people
- Sponsor
- University of Florida
Hepatitis C, Chronic
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a…
- Trial name
- NCT00062816
- Testing
- ISIS 14803, peginterferon alfa, ribavirin
- Where
- 25 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatitis C
TD-6450 SAD and MAD in Healthy Subjects
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
- Trial name
- NCT02022306
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Hepatitis C
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3…
- Trial name
- NCT02652377
- Testing
- EDP-494
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatic Fibrogenesis, Hepatitis C
Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression
The purpose of this study is to determine the effect of moderate alcohol intake on liver disease caused by HCV in terms of speed of progression as compared to those not drinking alcohol.
- Trial name
- NCT00205075
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Wisconsin, Madison
Hepatitis B Virus, Health Care Associated Infection
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
Hepatitis B virus (HBV) has infected over one third of the world's population; of these about 350 million go on to be chronic carriers.
- Trial name
- NCT04072211
- Testing
- Engerix-B
- Where
- Zambia
- Volunteers
- 641 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Hepatitis C
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1…
- Trial name
- NCT00938899
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Volunteers, Hepatitis C Virus
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
This is an adaptive Phase I study to evaluate RO5024048 in the following groups: Healthy Volunteers (Part 1 - Single Ascending Dose Study) -Enrollment completed Hepatitis C virus (HCV) genotype 1 infected patients who have failed…
- Trial name
- R7128 (NCT00382798)
- Testing
- RO5024048
- Where
- 9 sites in United States, New Zealand and 1 more
- Volunteers
- 75 people
- Sponsor
- Pharmasset
Hepatitis C
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
- Trial name
- NCT01979939
- Testing
- DCV/ASV/BMS-791325
- Where
- 66 sites in United States, Australia and 3 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Infection, Thrombocytopenia
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
- Trial name
- NCT01153919
- Testing
- romiplostim, ribavirin, PEG-interferon alfa-2a
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Hepatitis C
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study.
- Trial name
- NCT01721265
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Failure, Acute on Chronic, Liver Injury
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
The definition and diagnostic criteria of Acute-on-chronic liver failure (ACLF) has been well established by EASL CANONIC study. However, patients with high risk to develop ACLF has not been determined, yet.
- Trial name
- NCT03281265
- Testing
- standard treatment
- Volunteers
- 1,178 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B
A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA
Primary objective: To describe in subjects vaccinated with 3 doses of HEXAVAC® or 3 doses of INFANRIX®-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre ≥10 mIU/mL 1 month after a…
- Trial name
- NCT00693186
- Testing
- HBVaxPRO® 5 µg / 0.5 mL, Engerix B® 10 µg / 0.5 mL
- Where
- 5 sites in Italy
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatitis B
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.
- Trial name
- NCT01063036
- Testing
- Entecavir, Tenofovir
- Where
- 28 sites in France, Germany and 5 more
- Volunteers
- 144 people
- Sponsor
- Bristol-Myers Squibb
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
Acute Hepatitis C, HIV
The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals
The aim of the study is to investigate the epidemiology, natural history and treatment outcomes of acute hepatitis C (HCV) infection.
- Trial name
- PROBE-C (NCT01289652)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Benedetta Mattioli
Chronic Hepatitis B
Performance of Novel Simplified Score for Chronic Hepatitis B Treatment Eligibility in Thailand
International and national guideline for chronic hepatitis B (HBV) infection treatment recommend initiated antiviral in high HBV viral loads patients with significant liver inflammation and significant liver fibrosis.
- Trial name
- NCT05295914
- Testing
- TREAT-B score
- Where
- Thailand
- Volunteers
- 600 people
- Sponsor
- Mahidol University